Needham & Company LLC Reiterates Hold Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating restated by Needham & Company LLC in a report issued on Thursday,Benzinga reports.

A number of other research firms have also weighed in on OMER. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Rodman & Renshaw began coverage on shares of Omeros in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price objective on the stock. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Omeros Stock Up 0.7 %

OMER opened at $10.31 on Thursday. The stock’s fifty day moving average is $7.09 and its two-hundred day moving average is $5.18. The company has a market capitalization of $597.46 million, a P/E ratio of -4.46 and a beta of 1.97. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60.

Institutional Trading of Omeros

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP acquired a new position in Omeros during the 3rd quarter valued at about $305,000. Barclays PLC boosted its holdings in Omeros by 121.3% in the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock worth $376,000 after acquiring an additional 51,873 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after acquiring an additional 31,081 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Omeros during the second quarter valued at about $105,000. Finally, SG Americas Securities LLC purchased a new position in shares of Omeros in the 3rd quarter valued at approximately $80,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.